Health, a leader in complete cardiometabolic care, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), today ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Analysts have suggested that the US market for drugs to treat UDCA-refractory PBC could be worth $1.5 billion or more per year. Gilead acquired Livdelzi – an oral PPAR delta agonist ...

SAN DIEGO and DALLAS, June 17, 2025 /PRNewswire/ -- 9amHealth, a leader in complete cardiometabolic care, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), today announced a ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll ...

This satellite picture by Planet Labs PBC shows Iran's underground nuclear enrichment site at Fordo on March 19, 2025 ...

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

In addition many of these events, from Jupiter, to West Palm Beach down to Boca Raton and beyond, will include live music, ...

PARIS (AP) — Israel’s tally of the war damage it wrought on Iran includes the targeted killings of at least 14 scientists, an ...